Jane Street Group, LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $13.9 Million - $19.8 Million	481,000 New	481,000 $13.9 Million
Q1 2022 May 17, 2022	BUY	$35.46 - $54.12 $3.03 Million - $4.63 Million	85,500 Added 219.79%	124,400 $6.32 Million
Q4 2021 Feb 15, 2022	SELL	$30.74 - $49.16 $7.03 Million - $11.2 Million	-228,700 Reduced 85.46%	38,900 $1.84 Million
Q3 2021 Nov 16, 2021	BUY	$31.4 - $69.84 $5.55 Million - $12.3 Million	176,600 Added 194.07%	267,600 $8.82 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $1.19 Million - $1.9 Million	29,200 Added 47.25%	91,000 $5.75 Million
Q1 2021 May 18, 2021	BUY	$40.8 - $57.39 $620,160 - $872,328	15,200 Added 32.62%	61,800 $2.65 Million
Q4 2020 Feb 17, 2021	BUY	$30.79 - $57.2 $381,796 - $709,280	12,400 Added 36.26%	46,600 $2.67 Million
Q2 2020 Aug 17, 2020	BUY	$24.8 - $38.49 $848,160 - $1.32 Million	34,200 New	34,200 $1.12 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.